List of Lab Research Products Companies in South Korea - 11

Actnova is a South Korean startup specializing in AI SaaS solutions. The company platform automates the behavioral testing process in clinical and non-clinical fields with artificial intelligence image processing technology. Actnova is also a manufacturer of materials inspection, measurement, and analysis instruments.

Art Blood Co., Ltd. is a company that is building/developing a cell-based in vitro blood production system to solve the problem of blood for transfusion that is in short supply worldwide and has side effects. In addition, we are developing a platform to provide reagent red blood cells used to detect transfusion-related antibodies and therapeutic red blood cells that transport and express various therapeutic agents and immunostimulants.

CHA Bio Group is continuing its challenge to become the best in various initial achievements in the bio and healthcare fields. We are developing and producing advanced biopharmaceuticals, including cell and gene therapy products and vaccines, based on our global R&D capabilities, such as our unique ‘CHA Bio ecosystem': Academic, Research, Medical Network, and Bio-Industry Business, the world's largest cell library, and our independently developed vaccine adjuvant platform. We will leap forward as a true global bio company centered on the third-generation CGT CDMO and global healthcare business.

MEPSGEN, a biotech founded by YongTae Kim and Robert Langer in 2019, develops microengineered physiological systems so called organ-on-a-chip and uses the manufactured systems to study pathophysiological mechanisms of key diseases and screen new drug candidates for the treatment. With these studies supported by the technologies, the company has its own multiple new drug candidates, representative ones of which target Alzheimer's and brain tumors. The company specializes in developing and producing a 3D cell culture Microphysiological System platform and in discovering new therapeutics using nanomedicine technology. The products and services include improved accuracy in evaluating new drug candidates and reducing cost and duration of the development. The company carries out fundamental biological research and drug candidate test in an environment equipped with an organ-level function of connected human tissues, rather than studying in a traditional in-vitro experimental model using 2D cell culture, thereby enabling researchers to further verify the findings in more pathophysiologically relevant environments. MEPSGEN is holding many patents, patents pending, and numerous IP licenses in the biotechnology field. For more information visit www.mepsgen.com [ Industry ] Drug Discovery Drug Delivery Biotechnology [ Technology ] MEPS-X series - 3D Microphysiological System platforms MST-X series - Microvortex System, Nanoparticle manufacturing platform MG-X series – Nanomedicine, Biomimetic nanomaterial-based targeted drug delivery platforms

Novelty Nobility Inc. is a private clinical stage biotech company located in Pangyo, South Korea, and Boston, Massachusetts. We are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. Novelty Nobility, a unique name for a biotech company, stands for what we pursue – Novel Science, Noble Management. The emblem in the middle of our logo, which shapes a drug, symbolizes our belief that a new drug is born when novel science meets noble management.

[About ROKIT Healthcare] ROKIT Healthcare is a First Mover in regenerative healthcare, pioneering innovations that reduce medical costs for governments and patients while driving healthcare transformation. Our mission is to extend healthy lifespans and enhance quality of life through cutting-edge technologies. At the heart of our vision lies the AI Hyper-Personalized Organ Regeneration Platform, a revolutionary solution designed to meet critical medical needs and redefine the future of medicine. [What We Do] - AI-Driven Organ Regeneration: Combining advanced bioprinting and AI to deliver hyper-personalized therapies for organ and tissue regeneration. - Anti-aging Bio-suppliment Products: Leading the anti-aging market with NMN, offering scientifically proven and effective solutions for better health. (ROKIT America) - Genomics: Utilizing AI-powered single-cell RNA-seq analysis to develop innovative diagnostics and precision medicine. (ROKIT Genomics) [Why ROKIT Healthcare?] We are committed to creating a sustainable and innovative healthcare ecosystem that benefits governments, healthcare providers, and patients. By addressing the root causes of medical challenges and reducing costs, we aim to make advanced healthcare accessible to all. [ROKIT Healthcare에 대하여] - ROKIT Healthcare는 재생 의료 분야의 First Mover로서, 정부와 환자의 의료비를 절감하고 의료 혁신을 주도하는 기술과 아이디어를 선도하고 있습니다. -우리의 사명은 최첨단 기술을 통해 건강 수명을 연장하고 삶의 질을 향상시키는 것입니다. 이러한 비전의 핵심에는 AI Hyper-Personalized Organ Regeneration Platform이 자리 잡고 있으며, 이는 의료의 중요한 과제를 해결하고 미래 의료의 패러다임을 재정의하는 혁신적인 솔루션입니다. [우리가 하는 일] - AI 기반 장기 재생: 첨단 바이오프린팅과 AI를 결합하여 개개인 맞춤형 장기 및 조직 재생 치료를 제공합니다. - 항노화 바이오 보충제 제품: 과학적으로 검증된 NMN으로 항노화 시장을 선도하며 건강을 위한 효과적인 솔루션을 제공합니다. (ROKIT America) - 유전체학: AI 기반 단일 세포 RNA-seq 분석을 활용하여 혁신적인 진단 및 정밀 의학 솔루션을 개발합니다. (ROKIT Genomics) [ROKIT Healthcare가 특별한 이유] 우리는 정부, 의료 제공자, 그리고 환자 모두에게 혜택을 주는 지속 가능하고 혁신적인 의료 생태계를 만들기 위해 노력하고 있습니다. 의료 문제의 근본적인 원인을 해결하고 비용을 절감함으로써, 선진 의료 기술을 모두가 접근 가능하게 만드는 것을 목표로 하고 있습니다.

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.

Surginex is a company that operates a drug discovery platform intended to develop next-generation bio platforms and new drugs. The company specializes in 361 HCT/P allografts and is committed to turning innovative scientific research into practical medical solutions.

Toolgen is committed to conducting research for revamping genome editing technology and thus developing not only therapeutics for humans but plants and animals of which the genetic characters are modified by the editing.